ArriVent Biopharma

A Phase 3 biotech company developing a novel kinase inhibitor for the treatment of cancer.

The company is currently evaluating furmonertinib in multiple trials, including a pivotal phase 3 study in first-line patients with locally advanced or metastatic EGFRm NSCLC with exon 20 insertion mutations.

_____________________________
The number of employees:
30-50
_____________________________
Headquarters:

18 Campus Boulevard, Suite 100, Newtown Square, PA 19073, USA